Skip to main content

Table 1 Baseline demographics and clinical characteristics of pediatric subjects in the mOIT, rush mOIT, and control groups

From: Multiple-allergen oral immunotherapy improves quality of life in caregivers of food-allergic pediatric subjects

  mOIT* Rush mOIT* Control
Number of subjects 29 11 10
Median age in years (range) 8 (4 – 13) 7 (4 – 16) 8 (4–14)
Male 18 (62%) 8 (72%) 5 (50%)
Coexisting atopic disease  
 Atopic dermatitis 20 (69%) 5 (45%) 5 (50%)
 Allergic rhinitis 15 (52%) 6 (55%) 6 (60%)
 Asthma 21 (72%) 8 (73%) 7 (70%)
Food allergies meeting criteria for inclusion on DBPCFC**
 Peanut 20 (69%) 7 (64%) 7 (70%)
 Walnut 11 (38%) 5 (45%) 4 (40%)
 Cashew 9 (31%) 6 (55%) 3 (30%)
 Pecan 8 (28%) 5 (45%) 3 (30%)
 Milk 8 (28%) 3 (27%) 2 (20%)
 Egg 4 (14%) 4 (36%) 3 (30%)
 Sesame 4 (14%) 0 (0%) 2 (20%)
 Almond 3 (10%) 3 (27%) 2 (20%)
 Hazelnut 2 (7%) 1 (9%) 2 (20%)
Average number of desensitized foods
  3 4 n/a
Highest baseline food allergy test (median and range)
 SPT in mm 13.5 (7–25.5) 10.5 (7–29.5) 10.5 (7–30.5)
 Specific IgE in ku/L 82.5 (2.95- > 100) 36.4 (2- > 100) 61 (3.25- > 100)
 Lowest amount triggering reaction in DBPCFC in mg protein 32.7 (0.1-182.7) 32.7 (0.1-182.7) 32.7 (0.1-182.7)
  1. *OIT = oral immunotherapy. **DBPCFC = double blind placebo controlled food challenge.